BMS’s Anti-LAG3 Drug Could Offer Safer Combo Partner To Opdivo Monotherapy Patients

The first look at the numbers behind Bristol Myers Squibb Company’s immuno-oncology doublet combination of its anti-LAG3 antibody relatlimab and its PD-1 inhibitor Opdivo (nivolumab) show a combination that is less toxic than the combination of Opdivo with BMS’s CTLA-4 inhibitor Yervoy (ipilimumab), but also seems possibly slightly less effective. However, as the PD-1/LAG3 pairing was significantly more effective than Opdivo monotherapy it has the potential to address a significant population.

The company announced on 19 May data from the Phase II/III RELATIVITY-047 trial testing the two drugs administered as a single infusion in 714 patients with first-line metastatic or unresectable melanoma, which are slated for presentation in an